ArticleJournal of applied clinical medical physics2026
COMP Report: Patient-specific quality assurance practices in Canadian radiotherapy-results from a national survey.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient-specific quality assurance (PSQA) is an essential component of modern radiotherapy, ensuring safe and accurate delivery of increasingly complex treatments. Given its resource-intensive nature and the availability of evolving approaches, examining how PSQA is implemented and optimized across Canada is important to inform best practices. This study aimed to characterize the current landscape of PSQA practice across Canadian radiotherapy centers, identify patterns and regional variations, and explore opportunities for future national guidance. A 30-question web-based survey was developed and distributed in March 2024 to all Canadian radiotherapy centers, including satellites. The survey addressed staffing, treatment machines, PSQA tools and methodologies, policies, data analysis, frequency of PSQA, and failure management. Responses were collected in both English and French, de-identified, and analyzed by center size and region (British Columbia, Prairies, Ontario, Quebec, and Atlantic). The survey achieved a 90% response rate (45 of 50 centers). Most centers reported using 3D array detectors, followed by EPID and point detectors. Gamma index analysis was the predominant evaluation method. More than half of participating centers, including 65% of large centers, reported reducing PSQA measurement frequency, citing accumulated local experience rather than external guidance. However, all centers in the Prairies and Atlantic regions reported maintaining full measurement frequency. A vast majority of centers that used delivery log calculations also reported a reduction in measurement frequency, while most centers using EPID did not. Across all regions, selective adoption of recommendations from both Canadian and American guidelines was observed. PSQA practices in Canada are heterogeneous, reflecting local resources, institutional experience, and evolving international recommendations. Given the resource-intensive nature of PSQA and observed variability in practice, these findings highlight the value of developing national guidance tailored to Canadian clinical realities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.